Success Metrics

Clinical Success Rate
94.4%

Based on 134 completed trials

Completion Rate
94%(134/142)
Active Trials
10(6%)
Results Posted
27%(36 trials)
Terminated
8(5%)

Phase Distribution

Ph early_phase_1
2
1%
Ph not_applicable
11
7%
Ph phase_1
117
69%
Ph phase_2
21
12%
Ph phase_3
14
8%
Ph phase_4
4
2%

Phase Distribution

119

Early Stage

21

Mid Stage

18

Late Stage

Phase Distribution169 total trials
Early Phase 1First-in-human
2(1.2%)
Phase 1Safety & dosage
117(69.2%)
Phase 2Efficacy & side effects
21(12.4%)
Phase 3Large-scale testing
14(8.3%)
Phase 4Post-market surveillance
4(2.4%)
N/ANon-phased studies
11(6.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

91.2%

134 of 147 finished

Non-Completion Rate

8.8%

13 ended early

Currently Active

10

trials recruiting

Total Trials

169

all time

Status Distribution
Active(18)
Completed(134)
Terminated(13)
Other(4)

Detailed Status

Completed134
Terminated8
Not yet recruiting8
Recruiting6
Withdrawn5
Active, not recruiting4

Development Timeline

Analytics

Development Status

Total Trials
169
Active
10
Success Rate
94.4%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (1.2%)
Phase 1117 (69.2%)
Phase 221 (12.4%)
Phase 314 (8.3%)
Phase 44 (2.4%)
N/A11 (6.5%)

Trials by Status

terminated85%
active_not_recruiting42%
unknown42%
not_yet_recruiting85%
completed13479%
recruiting64%
withdrawn53%

Recent Activity

Clinical Trials (169)

Showing 20 of 169 trialsScroll for more
NCT06253715Phase 3

Shortened Regimen for Drug-susceptible TB in Children

Recruiting
NCT06489431Phase 3

Irrisept vs Traditional Antibiotic Irrigation for Virgin Penile Prosthesis Placement

Active Not Recruiting
NCT07242781Phase 1

A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult Male Participants

Terminated
NCT04933682Phase 1

Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants

Completed
NCT05221502Phase 2

Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB

Completed
NCT07600775Phase 1

A Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuberculosis Infection (MK-8527-019)

Not Yet Recruiting
NCT03301038Phase 2

Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria

Recruiting
NCT07595042Phase 2

A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB)

Not Yet Recruiting
NCT07550621Phase 1

Drug-Drug Interaction Study of MDR-001 With Rifampin and Itraconazole in Healthy Adult Participants

Not Yet Recruiting
NCT03012529Phase 4

Investigation of Rifampin to Reduce Pedal Amputations for Osteomyelitis in Diabetics

Completed
NCT05556746Phase 2

Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB

Active Not Recruiting
NCT03672630Phase 2

Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease

Completed
NCT07357610Phase 1

An Open-Label Drug Interaction Clinical Study to Evaluate Itraconazole, Rifampin, Midazolam and SIM0270 in Chinese Healthy Adult Participants

Recruiting
NCT04951986Phase 3

Testing New Strategies for Patients Hospitalised With HIV-associated Disseminated Tuberculosis

Active Not Recruiting
NCT05592223Phase 1

Phase I Open Label BCG Clinical Trial Assessing TB Drugs and Vaccines

Completed
NCT04606537Phase 1

Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects

Completed
NCT07253688Phase 3

Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus

Recruiting
NCT07018635Phase 1

A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants

Completed
NCT05766267Phase 2

Short-course Regimens for the Treatment of Pulmonary Tuberculosis

Active Not Recruiting
NCT02563327Phase 3

Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis

Completed

Drug Details

Intervention Type
DRUG
Total Trials
169